Want to see HK:1801 full AI Analyst Report?
Top Page
Innovent Biologics
(1801)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$117.00
▲(16.88% Upside)
Action:Downgraded
Date:08/27/26
The score is driven primarily by improved financial performance in 2025 (profitability and especially cash flow strength) and a conservative balance sheet, partially offset by an uneven multi-year track record. Technically the stock has strong momentum versus moving averages, but elevated RSI suggests near-term stretch. The biggest drag is valuation, with a very high P/E that raises expectation risk.
Positive Factors
Revenue and Margin Inflection
The 2025 revenue increase, sharp gross-margin improvement and return to profitability indicate stronger commercial execution. Sustaining these gains would improve operating leverage and provide a broader earnings base for funding Innovent’s pipeline.
Negative Factors
Uneven Cash-Flow History
Although 2025 cash generation was powerful, the preceding period shows inconsistent conversion and sustained free-cash-flow deficits. This history makes it difficult to assume the latest improvement is fully recurring and raises funding risk for ongoing R&D.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Inflection
The 2025 revenue increase, sharp gross-margin improvement and return to profitability indicate stronger commercial execution. Sustaining these gains would improve operating leverage and provide a broader earnings base for funding Innovent’s pipeline.
Read all positive factors
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$178.57B
Dividend YieldN/A
Average Volume (3M)13.25M
Price to Earnings (P/E)123.9
Beta (1Y)0.66
Revenue Growth42.64%
EPS Growth9.67%
CountryHK
Employees8,754
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.71
Shares Outstanding1,743,864,600
10 Day Avg. Volume15,524,848
30 Day Avg. Volume13,246,268
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$133.64Price Target Upside33.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)1.35
Revenue Forecast (FY)HK$18.62B
Innovent Biologics Business Overview & Revenue Model
Company Description
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encomp...
How the Company Makes Money
Innovent primarily makes money by selling its commercialized prescription biologic drugs, generating product sales revenue through distribution to hospitals and pharmacies (typically supported by a field sales organization and channels appropriate...
Innovent Biologics Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
76
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.59B | 13.04B | 9.42B | 6.21B | 4.56B | 4.27B |
| Gross Profit | 12.62B | 10.00B | 7.91B | 4.40B | 3.63B | 3.70B |
| EBITDA | 2.63B | 1.31B | -480.28M | -660.68M | -1.75B | -2.37B |
| Net Income | 1.22B | 813.57M | -94.63M | -1.03B | -2.18B | -2.73B |
Balance Sheet | ||||||
| Total Assets | 41.61B | 37.36B | 21.60B | 20.63B | 17.59B | 16.24B |
| Cash, Cash Equivalents and Short-Term Investments | 20.00B | 18.24B | 7.88B | 10.97B | 9.17B | 9.02B |
| Total Debt | 2.32B | 2.82B | 2.83B | 3.62B | 3.23B | 2.50B |
| Total Liabilities | 20.06B | 17.20B | 8.48B | 8.10B | 6.86B | 5.91B |
| Stockholders Equity | 20.74B | 19.36B | 13.12B | 12.53B | 10.73B | 10.33B |
Cash Flow | ||||||
| Free Cash Flow | 9.43B | 9.32B | -418.39M | -1.24B | -3.30B | -3.87B |
| Operating Cash Flow | 9.66B | 10.00B | 1.29B | 147.81M | -1.92B | -2.02B |
| Investing Cash Flow | -7.17B | -6.51B | -1.17B | -998.66M | -1.44B | -2.70B |
| Financing Cash Flow | 4.05B | 4.73B | -606.63M | 2.59B | 2.89B | 5.00B |
Innovent Biologics Technical Analysis
Positive
100.10
Price Trends
93.83
Positive
88.01
Positive
86.79
Positive
Market Momentum
2.97
Positive
55.40
Neutral
24.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1801, the sentiment is Positive. The current price of 100.1 is below the 20-day moving average (MA) of 100.60, above the 50-day MA of 93.83, and above the 200-day MA of 86.79, indicating a bullish trend. The MACD of 2.97 indicates Positive momentum. The RSI at 55.40 is Neutral, neither overbought nor oversold. The STOCH value of 24.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1801.
Innovent Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$41.22B | 4.19 | 30.16% | 1.56% | 101.73% | 249.15% | |
72 Outperform | HK$67.94B | 11.96 | 128.12% | ― | 305.94% | ― | |
64 Neutral | HK$38.22B | 37.75 | 20.41% | ― | 32.63% | 8.87% | |
63 Neutral | HK$178.57B | 123.86 | 6.06% | ― | 42.64% | 9.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$93.22B | -83.32 | -10.86% | ― | 42.47% | -15.80% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:1801
Innovent Biologics
101.30
0.40
0.40%
HK:1530
3SBio
16.04
-19.34
-54.66%
HK:9926
Akeso, Inc.
96.00
-44.10
-31.48%
HK:9995
RemeGen Co. Ltd. Class H
78.70
-25.70
-24.62%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.66
-19.18
-52.06%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.55
-20.35
-23.69%
Innovent Biologics Corporate Events
Innovent Biologics Reshapes Board Roles as Veteran Executive Retires from Full-Time Post
Aug 25, 2026
Innovent Biologics announced that long-serving executive director Ronald Hao Xi Ede will be re-designated as a non-executive director effective September 1, 2026, as he retires from full-time employment to focus on his family. Ede, a former chief ...
Innovent Biologics Delivers Strong First-Half 2026 Profit and Revenue Surge
Aug 25, 2026
Innovent Biologics reported a sharp rise in interim results for the six months ended 30 June 2026, with total revenue climbing 44.8% year on year to RMB8.62 billion and product revenue surging 56.7% to RMB8.20 billion. The company said the perform...
Innovent Biologics Sets Board Meeting to Approve 2026 Interim Results
Aug 10, 2026
Innovent Biologics, Inc. has scheduled a board meeting for August 25, 2026, to review and approve the interim results for the six months ended June 30, 2026. The company also plans to authorize the publication of these interim results, a key step ...
Innovent Biologics Posts Strong H1 2026 Revenue and Deepens Oncology, Global Expansion
Aug 5, 2026
Innovent Biologics reported total product revenue of over RMB8.2 billion for the first half of 2026, up more than 55% year-on-year, with second-quarter revenue exceeding RMB4.3 billion and growing about 60%. The strong performance was driven by it...
Innovent Biologics Shareholders Approve All AGM Resolutions, Strengthening Capital Flexibility
Jun 24, 2026
Innovent Biologics reported that all resolutions proposed at its annual general meeting held on June 24, 2026, were approved by shareholders via poll, including receipt of the 2025 audited financial statements and the re-election of key executive ...
Innovent Biologics Details Board and Committee Structure to Strengthen Governance
Jun 24, 2026
Innovent Biologics has disclosed the current composition of its board of directors, led by Chairman and Chief Executive Officer Dr. De-Chao Michael Yu alongside two other executive directors and five independent non-executive directors, including ...
Innovent Biologics Grants Share Options and Restricted Shares to Employees Under 2024 Scheme
Jun 15, 2026
Innovent Biologics has granted 5,000 share options and 105,200 restricted shares to 23 non-connected employees under its 2024 Share Scheme, with all recipients being non-senior staff within the group. The move reinforces the company’s incent...
Innovent’s Gastric Cancer ADC Wins China Priority Review After Phase 3 Success
Jun 4, 2026
Innovent Biologics said its antibody-drug conjugate arcotatug tavatecan (IBI343), targeting CLDN18.2, met the primary endpoint in an international phase 3 trial for heavily pretreated advanced gastric and gastroesophageal junction adenocarcinoma. ...
Innovent Biologics Sets June 2026 AGM With Share Buyback and Issuance Mandates on Agenda
May 29, 2026
Innovent Biologics has convened its annual general meeting for June 24, 2026 in Suzhou, where shareholders will review the company’s audited financial statements for 2025 and vote on the re-election of three directors, including one executiv...
Innovent Strikes Up to US$10.5 Billion Global Oncology Pact With Pfizer
May 28, 2026
Innovent Biologics has entered a global strategic licensing and collaboration agreement with Pfizer to research and develop 12 early-stage and de novo cancer medicines, including antibody-drug conjugates and multi-specific antibodies. The partners...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.